Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

Rhea-AI Summary

Ardelyx (NASDAQ: ARDX), a biopharmaceutical company focused on developing first-in-class medicines for unmet medical needs, has announced its participation in the upcoming Jefferies Global Healthcare Conference 2025. President and CEO Mike Raab will engage in a fireside chat on June 4, 2025, at 8:10 am ET in New York. The presentation will be accessible via live webcast on the company's website, with a replay available for 30 days following the event.

News Market Reaction – ARDX

-4.55%

-4.55% Session move

In the trading session that priced this news, ARDX declined 4.55%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will participate in a fireside chat at the Jefferies Global Healthcare Conference 2025 on Wednesday, June 4, 2025 at 8:10 am ET in New York.

To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ardelyx.com/. A replay of the fireside chat will be available on the Ardelyx website for 30 days following the event.

About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA^® (tenapanor) and XPHOZAH^® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL^® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com

FAQ

When is Ardelyx (ARDX) presenting at the Jefferies Global Healthcare Conference 2025?

Ardelyx's CEO Mike Raab will participate in a fireside chat on Wednesday, June 4, 2025, at 8:10 am ET in New York.

Who will represent Ardelyx (ARDX) at the Jefferies Healthcare Conference 2025?

Mike Raab, President and CEO of Ardelyx, will represent the company at the conference.

How can investors access Ardelyx's (ARDX) presentation at the Jefferies Conference?

Investors can access the live webcast through the Events and Presentations page on Ardelyx's website (ardelyx.com). A replay will be available for 30 days after the event.

What is Ardelyx's (ARDX) main business focus?

Ardelyx is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines that address significant unmet medical needs.